B型インフルエンザウイルス感染症(Influenza B Infections)の治療薬パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Influenza B Infections Overview 6
Therapeutics Development 7
Pipeline Products for Influenza B Infections – Overview 7
Pipeline Products for Influenza B Infections – Comparative Analysis 8
Influenza B Infections – Therapeutics under Development by Companies 9
Influenza B Infections – Therapeutics under Investigation by Universities/Institutes 10
Influenza B Infections – Pipeline Products Glance 11
Early Stage Products 11
Influenza B Infections – Products under Development by Companies 12
Influenza B Infections – Products under Investigation by Universities/Institutes 13
Influenza B Infections – Companies Involved in Therapeutics Development 14
AltraVax Inc. 14
Chimerix, Inc. 15
ContraFect Corporation 16
Crucell N.V. 17
Humabs BioMed SA 18
REPLICor Inc. 19
Influenza B Infections – Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 26
Drug Profiles 28
AL-18 – Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
CF-403 – Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
CR-8033 – Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
CR-8071 – Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
CR-9114 – Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Monoclonal Antibody for Influenza B Infections – Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
REP-9 – Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
seasonal influenza B vaccine – Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Small Molecules for Influenza B – Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Influenza B Infections – Dormant Projects 37
Influenza B Infections – Product Development Milestones 38
Featured News & Press Releases 38
Mar 11, 2011: Sanofi Pasteur And Daiichi Sankyo Announce Voluntary Recall Of Hemophilus Influenza Type B Conjugate Vaccine 38
Apr 23, 1993: FDA Approval of Use of a New Haemophilus b Conjugate Vaccine and a Combined Diphtheria-Tetanus-Pertussis and Haemophilus b Conjugate Vaccine for Infants and Children 38
Appendix 39
Methodology 39
Coverage 39
Secondary Research 39
Primary Research 39
Expert Panel Validation 39
Contact Us 40
Disclaimer 40